The FY24 Defense Appropriations Act provides funding for the Lung Cancer Research Program to support innovative, high-impact lung cancer research.
On Jan. 11, 1964, at a packed press conference for over 200 reporters at the U.S. State Department in Washington, DC, Surgeon General Luther L. Terry released what would become one of the most important and most widely cited documents in the annals of medicine: “Smoking and Health—Report of the Advisory Committee of the Surgeon General of the Public Health Service.”
Roy S. Herbst, deputy director of Yale Cancer Center and Smilow Cancer Hospital and assistant dean for translational research at Yale School of Medicine, was elected to the Friends of Cancer Research Board of Directors.
A report suggests that Lung-MAP, which for almost a decade has undergirded the first NCI-sponsored precision medicine clinical trial in lung cancer, can serve as a model for future clinical research that is more rapid, innovative, and inclusive.
At a time when distinguished careers can falter because of a careless Facebook post, the oncologist-iconoclast Vinay Prasad is showing no sign of moderating the shaming and haranguing that make him a social media phenom.
Vinay Prasad, a social media phenom and professor of epidemiology and biostatistics at the University of California, San Francisco, recently stunned his colleagues by stating that doctors at Vanderbilt University acted in a “despicable” manner when they offered a double lung transplant to a lung cancer patient. “The doctors at Vanderbilt are despicable in my... […]
Morhaf Al Achkar was named associate center director for education at the Barbara Ann Karmanos Cancer Institute.
University of New Mexico Comprehensive Cancer Center has opened a clinic to offer screening, minimally invasive testing, and follow-up for lung cancer as part of the institution’s lung cancer screening program.
Liquid biopsy tests may someday upend screening as we know it. The promise of broad screening employing “multi-cancer detection” has spawned consortia and inspired enthusiastic opinion articles.
Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102 (NCT05680922).
